menthol + camphor + sumatriptan

**Menthol + camphor + sumatriptan** is a combination migraine treatment kit marketed as **Migranow** and developed by **PureTek**. The product combines **oral sumatriptan succinate tablets** with a **topical camphor 4% and menthol 10% gel** in a roll-on applicator. Its principal pharmacologic anti-migraine component is **sumatriptan**, a **small-molecule selective serotonin 5-HT1B and 5-HT1D receptor agonist** that treats acute migraine by promoting cranial vasoconstriction and inhibiting trigeminal neuropeptide signaling. The menthol and camphor components are topical counterirritants intended to provide local analgesic or soothing effects. The product has been described for **acute migraine treatment**, including migraine with or without aura; the provided context also mentions cluster headache, but standard sumatriptan tablet labeling does not establish efficacy for cluster headache in this oral tablet setting. Based on the provided information, this is a **combination pharmaceutical product kit** rather than a novel single chemical entity, and it is noted in the context that it **has not received FDA approval for safety and efficacy as a branded combination product**.

Brand names

Migranow

Other names

menthol + camphor + sumatriptancamphor + menthol + sumatriptansumatriptan + camphor + menthol